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DNA replication is tightly coordinated both with cell cycle cues and with responses to extracellular signals
to maintain genome stability. We discovered that human Cdt1, an essential origin licensing protein whose
activity must be restricted to G1 phase, is a substrate of the stress-activated mitogen-activated protein (MAP)
kinases p38 and c-Jun N-terminal kinase (JNK). These MAP kinases phosphorylate Cdt1 both during unper-
turbed G2 phase and during an acute stress response. Phosphorylation renders Cdt1 resistant to ubiquitin-
mediated degradation during S phase and after DNA damage by blocking Cdt1 binding to the Cul4 adaptor,
Cdt2. Mutations that block normal cell cycle-regulated MAP kinase-mediated phosphorylation interfere with
rapid Cdt1 reaccumulation at the end of S phase. Phosphomimetic mutations recapitulate the stabilizing
effects of Cdt1 phosphorylation but also reduce the ability of Cdt1 to support origin licensing. Two other
CRL4Cdt2 targets, the cyclin-dependent kinase (CDK) inhibitor p21 and the methyltransferase PR-Set7/Set8,
are similarly stabilized by MAP kinase activity. These findings support a model in which MAP kinase activity
in G2 promotes reaccumulation of a low-activity Cdt1 isoform after replication is complete.
Precise and complete genome duplication presents a unique
challenge during the cell division cycle. To permit efficient
replication, DNA synthesis initiates at many chromosomal
sites, known as origins of DNA replication. During G1 phase,
origins are loaded with an inactive form of the DNA helicase
core, the minichromosome maintenance (MCM) complex.
Origins with loaded MCM complexes are “licensed” because
they are competent for replication initiation in the subsequent
S phase. MCM loading is accomplished through recruitment of
MCM complexes from the nucleoplasm by the Cdt1 protein to
an origin-bound assembly of the origin recognition complex
(ORC) and the Cdc6 protein. ORC and Cdc6 then load MCM
onto DNA (48, 57, 58).
Failure to properly control MCM loading can lead to repli-
cation errors and genome instability if insufficient origin licens-
ing occurs in G1 or if inappropriate origin relicensing occurs
after the onset of S phase. For example, high levels of Cdt1 or
Cdc6 activity in S or G2 phase can promote origin relicensing,
which leads to extensive rereplication and cell death; modest
deregulation of either Cdc6 or Cdt1 promotes genome insta-
bility and tumorigenesis (5, 28, 44). Thus far, the best-under-
stood mechanisms restricting origin licensing to G1 phase are
cell cycle-regulated accumulation and degradation of licensing
proteins and inhibition of several licensing proteins after S-
phase onset through phosphorylation by cyclin-dependent ki-
nases (CDKs) (7, 23, 34).
Given the critical need to maintain tight control and coor-
dination of origin licensing, it is likely that additional impor-
tant regulatory mechanisms have yet to be uncovered. Cell
cycle progression is arrested in response to a variety of cellular
stresses, including exposure to inflammatory cytokines, bacte-
rial toxins, osmotic shock, etc. (reviewed in references 19, 38,
41, and 68). Furthermore, the signaling pathways mediating
cell cycle arrest in response to such stresses are also active
during G2 and M phases even in the absence of exogenous
stress (14, 29, 42, 65), but little is known about how origin
licensing may be influenced by these pathways. We have investi-
gated the regulation of replication licensing factors by the stress-
activated mitogen-activated protein (MAP) kinases and have dis-
covered a direct link between these activities and control of the
stability and activity of the essential licensing protein, Cdt1.
MATERIALS AND METHODS
Cell culture and manipulations. HeLa cells were cultured in Dulbecco mod-
ified Eagle medium (DMEM) (Difco) supplemented with 10% fetal calf serum
(Sigma). Xeroderma pigmentosum group A (XPA)-deficient cells (GM04312)
with a documented defect in DNA repair and UV-inducible PCNA loading (3)
and their XPA-positive (XPA) derivative (GM15879) were obtained from the
Coriell Institute (GM15879) and cultured in DMEM plus 10% fetal calf serum.
HCT-116 cells were cultured in McCoy’s medium plus 10% fetal calf serum.
HeLa cells were synchronized in early S phase by double thymidine block or in
prometaphase by treatment with 2 mM thymidine for 18 h followed by release
into 100 nM nocodazole for 10 h. Stress treatments included supplementation to
350 to 500 mM sorbitol, 100 g/ml tumor necrosis factor alpha (TNF-), or 100
ng/ml lipopolysaccharide (LPS) (each from Sigma) or dimethyl sulfoxide
(DMSO) as controls. Mitogen-activated protein (MAP) kinase inhibitors
(Sigma) were used at the following concentrations: p38 inhibitor SB203580 at 30
M and c-Jun N-terminal kinase (JNK) inhibitor SP600125 at 100 M. The
concentration of SB203580 was selected as the amount necessary to block the
sorbitol-induced phosphorylation of MAP kinase-activated protein kinase 2
(MAPKAP-K2) in our cell lines (not shown). The MEK inhibitor was used at 50
M (compound UO126 from Promega), and the MAPKAP-K2 inhibitor was
used at 150 M (Calbiochem). Cells were transfected with plasmids using
0.005% polyethylenimine (Sigma). DNA damage was generated by a single dose
of 20 J/m2. Bromodeoxyuridine (BrdU) labeling and flow cytometry were carried
out as described previously (52). Significance testing utilized the Student t test on
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a minimum of three biological replicates. Plasmid transfections were performed
with polyethylenimine; small interfering RNA (siRNA) transfections were per-
formed with 100 nM (each) siRNA duplex using Dharmafect 1 reagent (Dhar-
macon) according to the manufacturer’s guidelines for 48 to 72 h for depletion
of p38 and Cdt1; JNK siRNAs were used at 250 nM. Synthetic duplexed RNA
oligonucleotides were synthesized by Invitrogen; their sequences are provided in
Table 1.
Antibodies. Antibodies were purchased from the following sources: p38, phos-
pho-p38, c-Jun N-terminal kinase 1 (JNK1), and JNK2, phospho-JNK1, and
JNK2, MAPKAP kinase 2, phospho-MAPKAP kinase 2, and PR-Set7/Set8 from
Cell Signaling Technologies; Cdc6 (sc-9964), PCNA (PC-10), and hemagglutinin
(HA) from Santa Cruz Biotechnology; MCM complex component 2 (Mcm2)
(BM28) and origin recognition complex (ORC) subunit 2 (Orc2) from BD
Pharmingen; p21 (Ab-10) from Neomarkers; V5 from Invitrogen; green fluores-
cent protein (GFP) (JL-8) from Clontech; and alpha-tubulin (DM1A) from
Sigma. Antibodies to detect Cul4A and DDB1 were a gift from Y. Xiong
(University of North Carolina), and Cdt2 antibody was a gift from A. Dutta
(University of Virginia). Antibodies to human Cdt1 have been previously de-
scribed (16). Detection of phosphorylation-dependent Cdt1 mobility shifts re-
quired precasting polyacrylamide gels at least 16 h prior to extended electropho-
resis in ice-cold Tris-glycine buffer. Phosphorylated peptide antigens (PRPALP
A[pT]PPA[pT]PPAA[pS]PSALK and TIM[pS]PGEMEKHL where pT is
phosphorylated threonine and pS is phosphorylated serine) were designed, syn-
thesized, and used for rabbit immunizations by 21st Century Biochemicals (Mar-
lboro, MA).
Plasmids and recombinant protein preparation. Plasmids for expressing glu-
tathione S-transferase (GST)–Cdt1 fusions were generated by recombinational
cloning (Gateway LR clonase; Invitrogen) between pENTR-Cdt1 derivatives and
pDEST15 for N-terminal GST fusions or pDEST24 for C-terminal fusions.
Plasmids for transient-transfection assays were generated by recombination with
pcDNA-DEST40 which introduces a C-terminal V5 epitope tag. Stable cell lines
were constructed by subcloning the Cdt1 cDNAs into pCLXSN (51) and pack-
aging into retroviral particles by standard protocols in 293T cells followed by
selection in 500 g/ml G418 (Gibco). Silent mutations to render Cdt1 siRNA
resistant (beginning with codon 519, ACA TAT GTG AAA CTC GAT [silent
mutations underlined]) were introduced by standard cloning methods. GST
fusions were partially purified from protease-deficient Escherichia coli (BL21;
Invitrogen) as previously described (16).
Chromatin fractionations and protein interaction assays. Chromatin fraction-
ations were carried out as previously described (17). Whole-cell lysates for
immunoprecipitation were prepared in CSK buffer (17) containing S7 micrococ-
cal nuclease and CaCl2 to release chromatin-bound material into the soluble
pool and clarified by centrifugation. Supernatants were then diluted with coim-
munoprecipitation (co-IP) buffer (50 mM HEPES [pH 7.2], 33 mM potassium
acetate [KAc], 0.5 mM EGTA, 0.1% NP-40, 10% glycerol, and protease and
phosphatase inhibitors).
In vitro kinase assays. Purified p38 (Cell Signaling Technologies) was incu-
bated with recombinant protein collected from 100 to 300 ml of bacterial culture
in kinase reaction buffer (50 mM Tris-HCl [pH 7.5], 10 mM MgCl2, and 1 mM
dithiothreitol [DTT]). Kinase reaction mixtures included 1 M ATP and 5 Ci
[-32P]ATP (Perkin Elmer) at 30°C. The kinase reaction was followed by SDS-
PAGE and autoradiography. For kinase reactions involving immunoprecipitated
MAP kinase or complexes formed on GST-Cdt1 bound to glutathione-agarose
beads, roscovitine (Sigma) was included at 25 M to inhibit any coprecipitating
cyclin-dependent kinase (CDK).
RESULTS
Cdt1 is phosphorylated by the p38 and JNK stress-activated
MAP kinases. Human Cdt1 is actively degraded throughout S
phase, but it reaccumulates once replication is complete (55);
this pattern is evident in HeLa cells synchronized by double
thymidine block and release (Fig. 1A, lanes 2 to 5). Early work
suggested that the Cdt1 inhibitor geminin is responsible for
stabilizing Cdt1 during G2 and M phases (8, 49). However,
subsequent investigation revealed that the reason for Cdt1
degradation in geminin-depleted cells is explained by rerepli-
cation-associated DNA damage when geminin is downregu-
lated (30). Thus, under normal growth conditions, geminin
cannot account for Cdt1 stability after the completion of S
phase. Cdt1 in G2 and M phase cells is known to exhibit
phosphorylation-dependent changes in gel mobility (33, 55).
We note that both p38 and c-Jun N-terminal kinase (JNK)
activities are naturally high in G2 and mitosis even in the
absence of an exogenous stress (Fig. 1A, lane 5) (12, 14, 15,
43). To test whether Cdt1 phosphorylation late in the cell cycle
is MAP kinase dependent, we held cells in prometaphase
(G2/M) with nocodazole, conditions that also induce high p38
and JNK activity (64, 69), and then treated the cells with p38
and JNK inhibitors. Within 1 h of inhibitor treatment, we found
that endogenous Cdt1 converts to a faster-migrating form and
is also reduced in overall abundance (Fig. 1B).
To determine whether exogenous activators of p38 and JNK
also induce Cdt1 phosphorylation, we treated asynchronous
HeLa cells with sorbitol to acutely and synchronously activate
the stress kinase pathway by osmotic shock (22, 68). Strikingly,
the Cdt1 protein reproducibly displayed reduced electropho-
retic mobility on SDS-polyacrylamide gels in response to os-
motic stress (Fig. 1C, lane 2). This mobility shift was reversed
by phosphatase treatment, demonstrating that Cdt1 is induc-
ibly phosphorylated during a stress response (Fig. 1C, lane 4).
Cdt1 was robustly phosphorylated within 5 min after the addi-
tion of sorbitol and just as rapidly as the activation of p38 itself
(Fig. 1D). Furthermore, this phenomenon was not an idiosyn-
crasy of HeLa cells, since Cdt1 was phosphorylated in a variety
of cell lines, including primary diploid fibroblasts (Fig. 1E).
Cdt1 also showed the same reduced gel mobility in cells treated
with the inflammatory cytokine tumor necrosis factor alpha
(TNF-) or the bacterial toxin lipopolysaccharide (LPS) (Fig.
1F), two additional activators of the cellular stress response
distinct from osmotic shock.
The only previously identified Cdt1 kinases are the cyclin-
dependent kinases (CDKs) (45, 62), but stress signaling inhib-
its rather than stimulates CDK activity, suggesting that CDKs
were not responsible for stress-induced Cdt1 phosphorylation
(47, 68). Moreover, a Cdt1 mutant lacking the cyclin binding
motif (45, 62) was still phosphorylated in sorbitol-treated cells
(data not shown). To determine whether Cdt1 phosphorylation
requires p38 and JNK activity, we treated cells with sorbitol in
the presence of p38 and/or JNK inhibitors. Neither inhibitor
alone had any detectable effect, whereas treatment with both
inhibitors completely blocked Cdt1 phosphorylation as mea-
sured by the gel mobility shift (Fig. 1G, compare lanes 2 and 8).
Inhibitors of the p38 target MAPKAP-K2 (MAP kinase-acti-
vated protein kinase 2) or the upstream activator of the related
MAP kinases, Erk1 and Erk2, had no effect on Cdt1 (data not
shown). To confirm that the effects of the pharmacological
inhibitors were specific for their intended targets, we also
transfected cells with small interfering RNA (siRNA) mole-
cules to deplete both p38 and p38 (Fig. 1H, lanes 3 and 4)
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or both JNK1 and JNK2 (Fig. 1H, lanes 5 and 6) or to simul-
taneously deplete all four of these MAP kinase isoforms (Fig.
1H, lanes 7 and 8). As with the inhibitor treatments, sorbitol
induced Cdt1 phosphorylation in cells expressing either p38 or
JNK, but not in cells depleted of both p38 and JNK (Fig. 1H,
compare lanes 2 and 8), indicating that the two kinases are
redundant in this setting. We concluded that Cdt1 is phosphor-
ylated in both acutely stressed cells and in G2/M phase and that
this phosphorylation is dependent on p38 and JNK, suggesting
that Cdt1 may be a MAP kinase substrate.
MAP kinases often form stable associations with their bona
fide substrates (9, 66). To test whether Cdt1 associates with a
stress-inducible kinase, we produced GST, GST-Cdt1, or a
truncated version that lacks amino acids 321 to 546, GST-
Cdt1C. We immobilized these proteins on glutathione beads
and then exposed them to cell extracts. Full-length Cdt1, but
not Cdt1C or GST, retrieved a sorbitol-inducible kinase from
cell lysates that phosphorylated GST-Cdt1 in vitro (Fig. 2A,
compare lanes 2 and 5), and this kinase(s) was sensitive to the p38
and JNK inhibitors (Fig. 2A, compare lanes 5 and 8). Moreover,
endogenous Cdt1 immunoprecipitated from cell lysates bound
endogenous p38 and JNK. Cdt1 bound p38 and JNK under both
stressed and unstressed conditions (Fig. 2B, lanes 4 and 5), a
behavior typical of other MAP kinase substrates (9, 66).
Finally, we activated p38 and JNK by a molecular genetic
approach. We transfected cells with a plasmid encoding V5-
tagged Cdt1 (Cdt1-V5) plus a plasmid encoding hemagglutinin
(HA)-tagged MEK kinase 3 (MEKK3) lacking its autoinhibi-
tory domain. This form of MEKK3 stimulates downstream
activation of p38 and JNK even in the absence of extracellular
signals (25). When coexpressed with active MEKK3, Cdt1-V5
underwent a mobility shift even in the absence of a signal (Fig.
2C, compare lanes 4 and 5). A catalytically inactive mutant of
MEKK3 (kinase dead [KD]) had no effect on Cdt1-V5 (Fig.
2C, lane 6). These results combined with the results of phar-
macological, genetic, and biochemical analyses above demon-
strate that Cdt1 is a substrate for stress-activated MAP kinases
both in vitro and in vivo.
Cdt1 phosphorylation requires five consensus MAP kinase
sites. The results of the GST-pulldown experiments (Fig. 2A)
suggested that stress-induced Cdt1 phosphorylation sites are C
terminal to amino acid 320 and distinct from the site of CDK-
mediated phosphorylation at T29 (63). Our tests of additional
truncation mutants of Cdt1 narrowed the primary phosphoac-
ceptor region to sites C terminal to amino acid 388 (data not
shown). MAP kinases require a proline at the 1 position
relative to the phosphoacceptor serine or threonine (4). We
converted five such conserved sites in Cdt1 to alanine one at a
FIG. 1. Stress triggers MAPK-dependent phosphorylation of Cdt1. (A) Lysates from HeLa cells synchronized by double thymidine block and
release were probed for the indicated endogenous antigens (e.g., phos-p38, phosphorylated p38). The position of a nonspecific band is indicated
by the asterisk to the left of the gel. async., asynchronous; hrs, hours. (B) HeLa cells were arrested in prometaphase by thymidine-nocodazole
synchronization and then treated with a combination of p38 and c-Jun N-terminal kinase (JNK) inhibitors () or mock treated () for 1 h prior
to harvest and detection of endogenous Cdt1. (C) Asynchronous HeLa cells were treated with 500 mM sorbitol for 60 min. Cell lysates were
resolved by SDS-PAGE, and endogenous Cdt1 was detected by immunoblotting. For lanes 3 and 4, lysates were treated with a mixture of calf
intestinal phosphatase and lambda phosphatase (in the absence of phosphatase inhibitors) prior to electrophoresis. The gel was prepared and
electrophoresed using conditions optimized to detect phosphorylation-dependent mobility changes as described in Materials and Methods.
(D) Lysates from HeLa cells treated with sorbitol for the indicated times were immunoblotted to detect endogenous Cdt1, phosphorylated p38
(phospho-p38), and total p38. (E) Primary human diploid fibroblasts were treated with sorbitol, and lysates were incubated with protein
phosphatase as indicated prior to analysis of endogenous Cdt1. (F) HeLa cells were treated with sorbitol for 30 min, 100 ng/ml lipopolysaccharide
(LPS) for 60 min, or 100 g/ml tumor necrosis factor alpha (TNF) for 60 min. Lysates were probed for the indicated proteins by immunoblotting.
(G) HeLa cells were treated with MAPK inhibitors (inhib.) for 15 min prior to sorbitol treatment, and lysates were probed with anti-Cdt1 antibody or
phosphorylated MAPK-activated protein kinase 2 (phos-MK2) antibody. (The p38 inhibitor was SB203580, and the JNK inhibitor was SP600125.)
(H) HeLa cells were transfected with control small interfering RNA (siRNA) targeting green fluorescent protein (GFP) (lanes 1 and 2), siRNA molecules
targeting p38 and p38 (lanes 3 and 4), siRNA targeting JNK1 and JNK2 (lanes 5 and 6), or siRNA simultaneously targeting all four stress-activated
MAPK isoforms (lanes 7 and 8) for 60 h and then mock treated or treated with sorbitol as indicated. Endogenous Cdt1, p38, p38, JNK1, and JNK2
were detected by immunoblotting. The p38 and p38 isoforms are recognized by the same antibody and migrate together by SDS-PAGE.
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time and expressed them as GST fusions in bacteria. Each of
the single mutants was phosphorylated virtually as robustly as
normal Cdt1 by p38 in vitro (data not shown). We then created
several combinations of alanine substitutions generating dou-
ble and triple mutants and a form of Cdt1 in which all five sites
were simultaneously converted to alanine. The double and
triple mutants were still phosphorylated by p38 in vitro, albeit
to a lesser extent than wild-type Cdt1 was (Fig. 3A, compare
lanes 6, 8, and 10 to lane 3). In contrast, Cdt1 phosphorylation
was barely detectable when all five phosphorylation sites were
converted to alanines (Cdt1-5A), demonstrating that we had
identified all of the major p38 target sites for in vitro phos-
phorylation (Fig. 3A, lane 12).
To test whether these five sites were required for MAP
kinase-mediated Cdt1 phosphorylation in vivo, we created a
panel of cell lines stably expressing near-endogenous levels of
normal Cdt1, Cdt1-5A, or a new mutant form in which the two
threonines were converted to glutamic acid and the three ser-
ines were converted to aspartic acid (Cdt1-2E3D). Ectopically
expressed Cdt1-5A showed no detectable change in gel mobil-
ity in response to sorbitol, indicating that the site(s) responsi-
ble for the shift had been altered (Fig. 3B, lane 6). Moreover,
the Cdt1-2E3D mutant showed reduced gel mobility even in
untreated cells (Fig. 3B, lane 7), suggesting that at least one of
these mutations mimics the effects of phosphorylation on Cdt1
gel mobility. To determine whether the MAP kinase target
sites are also responsible for Cdt1 phosphorylation in G2/M
cells, we synchronized cells by thymidine-nocodazole arrest.
For this experiment, we created stable cell lines expressing
native Cdt1 (without the epitope tag) but eliminated endoge-
nous Cdt1 by siRNA transfection during the release from thy-
midine into nocodazole. The Cdt1 constructs used to create
these cell lines harbor synonymous mutations in the binding
site for the cdt1 siRNA. Since Cdt1 is actively degraded during
S phase (e.g., Fig. 1A and reference 53), the presence of cdt1
siRNA prevents the reaccumulation of endogenous Cdt1 in the
subsequent G2 phase. By waiting until cells have entered early
S phase before siRNA addition, this protocol allows normal
origin licensing in G1 and thus normal S-phase progression,
because Cdt1 is not required for replication after origin licens-
ing is complete. All of the cells reached G2 DNA content on
schedule (confirmed by flow cytometry [not shown]), but cells
treated with cdt1 siRNA during S phase lacked Cdt1 protein in
the subsequent G2/M phase (Fig. 3C, compare lanes 1 and 3).
The cells were then released from the nocodazole block for 2 h
by mitotic shake-off. As expected, both endogenous Cdt1 and
normal ectopic Cdt1 (wild type [WT]) had slower gel mobility
in G2 cells than in G1 cells (Fig. 3C, compare lanes 1 and 5 to
lanes 2 and 6). Strikingly, mutation of the Cdt1 MAP kinase
sites to unphosphorylatable alanine (Cdt1-5A) completely
blocked the nocodazole-induced mobility shift (Fig. 3C, lanes 7
and 8), whereas the Cdt1-2E3D mutant constitutively re-
mained in the slower-migrating form (Fig. 3C, lanes 9 and 10),
indicating that these sites are responsible for Cdt1 gel mobility
changes in G2/M. It should be noted that the gel mobility shift
may be caused by phosphorylation at only a subset of the five
sites and furthermore, some amino acids may be phosphory-
lated by MAP kinases but have no effect on Cdt1 mobility.
Thus, although it is a useful indicator of Cdt1 targeting by
MAP kinases, we do not presume that altered gel mobility
demonstrates phosphorylation at all five sites.
We then raised phosphospecific antibodies using two differ-
ent Cdt1 peptides. One peptide was triply phosphorylated at
the cluster of MAP kinase sites at amino acids 402, 406, and
FIG. 2. Cdt1 associates with stress-inducible MAP kinases. (A) Cells were subjected to sorbitol treatment with or without prior treatment with
the p38 and JNK MAPK inhibitors as indicated. Cell lysates were incubated with recombinant GST fusion protein GST-Cdt1 (amino acids 1 to
546) or GST-Cdt1C (amino acids 1 to 320) immobilized on glutathione-Sepharose beads. Bound complexes were then incubated in kinase buffer
with [-32P]ATP, and phosphorylated substrates were detected by autoradiography. Total protein in the reaction mixture was detected by
Coomassie blue staining. (The position of a nonspecific band in the control GST preparation is indicated by the asterisk to the left of the gel [lanes
1, 4, and 7]. The absence of an obvious phosphorylation-dependent mobility shift reflects the different electrophoresis conditions needed in this
experiment.) (B) Endogenous Cdt1 was isolated from lysates of sorbitol-treated or mock-treated cells using anti-Cdt1 antibody or normal rabbit
serum as a control (ctrl). Proteins coimmunoprecipitating with Cdt1 were analyzed by immunoblotting with antibodies to detect endogenous p38
and JNK. IP, immunoprecipitation. (C) Cells were transfected with plasmids encoding HA-MEKK3N (hemagglutinin [HA]-tagged MEK kinase
3 lacking its autoinhibitory domain, constitutively active) or a kinase dead (KD) version of MEKK3N and cotransfected with plasmid encoding
V5-tagged Cdt1 (Cdt1-V5). Cells were treated with sorbitol as indicated and probed with V5 and HA antibodies to detect the ectopic proteins.
The loading control is a nonspecific background band.
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411; the second peptide included Ser491. The antisera were
used for immunoprecipitation with lysates of naïve or sorbitol-
treated cell lines expressing V5-tagged Cdt1, and those immu-
noprecipitates were then probed for the V5 epitope. Both the
phospho-402/406/411 (phosphorylated amino acids at positions
402, 406, and 411) and the phospho-491 antibodies efficiently
precipitated normal Cdt1 from lysates of sorbitol-treated cells
(Fig. 3D, lanes 7 and 11). Moreover, Cdt1-5A was not recog-
nized by either antibody even in lysates of sorbitol-treated
cells, indicating that Cdt1 is phosphorylated both on Ser491
and in the 402/406/411 region in vivo. Both phospho-specific
antibodies also immunoprecipitated endogenous Cdt1 from
lysates of nocodazole-arrested cells, but not from lysates of G1
cells (Fig. 3E, compare lanes 4 and 6 with lanes 5 and 7). The
use of these antibodies confirms that Cdt1 is phosphorylated
on at least 2 of the 5 (and most likely at least 4 of the 5) MAP
kinase sites in the C-terminal region of Cdt1 in vivo both
during an acute cellular stress response and during G2 phase.
MAP kinase-dependent phosphorylation stabilizes Cdt1.
Since treatment of nocodazole-arrested cells with MAP kinase
inhibitors led to a decrease in Cdt1 abundance (Fig. 1B), we
considered the possibility that MAP kinase phosphorylation
directly affects Cdt1 stability. We treated cells with sorbitol to
acutely induce Cdt1 phosphorylation and then UV irradiated
these cells to rapidly and synchronously trigger Cdt1 polyubiq-
uitination by CRL4Cdt2 (32). In the absence of sorbitol, DNA
damage induced the expected degradation of Cdt1 (Fig. 4A,
lanes 2 and 3). Strikingly, however, brief sorbitol pretreatment
completely blocked the degradation of Cdt1 induced by UV
irradiation (Fig. 4A, lanes 6 and 7). Cdt1 phosphorylation
induced by presynchronization with nocodazole also blocked
UV-induced degradation (data not shown). Stress signaling did
not block UV-induced degradation of Cdc6 and thus did not
prevent DNA damage (data not shown). Incubation of cells
with p38 and JNK inhibitors prior to UV irradiation not only
blocked Cdt1 phosphorylation as before but also restored Cdt1
susceptibility to UV-induced degradation (Fig. 4A, compare
lanes 13 and 14 to lanes 6 and 7).
Cdt1 degradation during S phase and after UV damage
requires interaction with the Cul4 E3 ubiquitin ligase complex
through an adaptor protein, Cdt2 (31, 37). Two other sub-
strates of the human CRL4Cdt2 complex have been identified,
the p21 CDK inhibitor and the PR-Set7 methyltransferase
(also known as Set8) (1, 2, 13, 67). Interestingly, p21 is also a
substrate for stress-activated MAP kinases (40). We ob-
served—as had others before (2, 10)—that p21 protein is
downregulated after UV irradiation (Fig. 4B, lanes 2 and 3).
We further found that like Cdt1, p21 was not targeted for
FIG. 3. Five sites in Cdt1 are phosphorylated by stress-inducible MAP kinases. (A) Recombinant full-length N-terminal GST-Cdt1 fusion
proteins were incubated with active p38 in the presence of [-32P]ATP followed by autoradiography. Total Cdt1 was detected by Coomassie blue
staining (note the mobility shift in the phosphorylated substrates). The mutated residues in the different GST-Cdt1 constructs are as follows: S372A
T402A T406A for 3A-1, T402A T406A S411A for 3A-2, S372A S491A for 2A, and S391A T402A T406A S411A S491A for 5A (in subsequent
analysis, S372 was not important for Cdt1 phosphorylation in vitro and thus was not included in the 5A mutant). The substrate for the reaction
in lane 1 is GST alone. WT, wild type. (B) HCT-116 cells stably expressing WT Cdt1, Cdt1-5A, or Cdt1-2E3D (S391D T402E T406E S411D S491D)
were subjected to sorbitol treatment as indicated. Ectopic Cdt1 or endogenous phospho-p38 and p38 were detected by immunoblotting. (C) HeLa
cells stably expressing (untagged) WT Cdt1, Cdt1-5A, or Cdt1-2E3D were synchronized in early S phase by double thymidine block and then
released into transfection medium containing cdt1 siRNA or control siRNA plus nocodazole (Noc.) for 10 h. The ectopic Cdt1 expression
constructs harbor synonymous mutations at the siRNA binding site. Cells were then released into G1 for 2 h prior to analysis by immunoblotting
with anti-Cdt1 antibody. We confirmed that the cells had completed S phase at the G2 time points (data not shown). The position of a nonspecific
band is indicated by the asterisk to the left of the gel. (D) HeLa cells stably expressing V5-tagged WT Cdt1 or Cdt1-5A were treated with 0.5 M
sorbitol () or treated with PBS () as a control for 30 min. Lysates were then immunoprecipitated with crude antisera raised against
phosphorylated Cdt1 peptides (phosphorylated threonines at positions 402, 206, and 411 [pT402/T406/T411] and phosphorylated serine at position
491 [p491]) and then probed for the V5 tag. The control immunoprecipitate with normal rabbit serum (NS) is indicated. The antibody heavy chain
is labeled IgG. (E) HeLa cells were synchronized in G2 by sequential thymidine and nocodazole treatments and then released into G1 for 2 h.
Lysates were immunoprecipitated with phospho-specific Cdt1 antisera and then probed for endogenous Cdt1. The control immunoprecipitate with
normal rabbit serum (NS) is indicated. The positions of the antibody heavy chain (IgG) and a nonspecific band (asterisk) are indicated to the left
of the gel.
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degradation by CRL4Cdt2 in cells pretreated with sorbitol to
activate the stress MAP kinases (Fig. 4B, lanes 5 and 6). Also
like Cdt1, inhibitors of stress-activated MAP kinases reversed
this effect, rendering p21 once again susceptible to degradation
(Fig. 4B, lanes 8 and 9). In addition, we observed the same
MAP kinase-dependent stabilization of PR-Set7 (Fig. 4C).
Cellular stress did not affect the abundance of the CRL4Cdt2
E3 ligase components themselves, arguing against global sta-
bilization of CRL4Cdt2 substrates by downregulating the E3
ligase subunits (data not shown).
To further investigate the mechanism of Cdt1 stabilization,
we tested whether the phosphorylation sites in Cdt1 are re-
quired for UV resistance. We transfected cells with plasmids
encoding normal Cdt1, the unphosphorylatable Cdt1-5A mu-
tant, or the phosphomimetic 2E3D mutant. Although normal
Cdt1 was resistant to UV-induced degradation after MAP ki-
nase activation, Cdt1-5A was still susceptible to degradation
even in the presence of activated MAP kinase (Fig. 4D, com-
pare lanes 5 and 9). Furthermore, Cdt1-2E3D was not sensitive
to UV-induced degradation under any conditions (Fig. 4D,
lanes 11 and 13). We note that both p38 and JNK are also
activated by UV irradiation (19, 68), but Cdt1 is degraded after
DNA damage. In the absence of Cdt1 phosphorylation before
UV treatment, however, Cdt1 was mostly degraded before the
kinases were activated (Fig. 4E, lanes 5 and 6), indicating that
the rapid kinetics of Cdt1 degradation after UV treatment
preclude stabilization by UV-activated p38 or JNK. Thus, Cdt1
phosphorylation at one or more of the five MAP kinase sites
blocks subsequent DNA damage-induced degradation.
Phosphorylation protects Cdt1 from CRL4Cdt2 after DNA
damage and in G2 phase by interfering with binding to Cdt2.
Interaction of Cdt1 with CRL4Cdt2 is dependent on Cdt1 bind-
ing to the sliding clamp PCNA, and PCNA must also be loaded
onto DNA for a productive interaction between Cdt1 and the
Cul4 adaptor Cdt2. This requirement for loaded PCNA applies
to both S-phase Cdt1 degradation and to UV-induced degra-
dation of Cdt1 (6, 54, 59). For example, human cells that fail to
efficiently load PCNA during UV-induced nucleotide excision
FIG. 4. MAPK-mediated phosphorylation prevents UV-mediated degradation of three substrates of the CRL4Cdt2 ubiquitin ligase. (A) Asyn-
chronous HeLa cells were subjected to UV irradiation, sorbitol treatment, and combined treatments in the presence and absence of MAPK
inhibitors as indicated. Sorbitol (Sorb) and/or inhibitors were added 15 min prior to UV irradiation. The cells were harvested at the indicated times
(in minutes), and the lysates were analyzed by immunoblotting with anti-Cdt1 antibody. A nonspecific band serves as a loading control. (B) Lysates
of cells irradiated and/or treated with p38 and JNK inhibitors as described above for panel A for the indicated times (in hours) were analyzed for
endogenous p21 and tubulin proteins by immunoblotting. (C) Lysates of cells irradiated and/or treated with p38 and JNK inhibitors as In panel
A for the indicated times were analyzed for endogenous PR-Set7/Set8 by immunoblotting. A nonspecific band serves as a loading control.
(D) HeLa cells transfected with plasmids encoding WT Cdt1, Cdt1-5A (unphosphorylatable) or Cdt1-2E3D (phosphomimetic) mutants were
treated with UV and sorbitol as indicated and analyzed by immunoblotting with anti-Cdt1 antibody. (E) HeLa cells were UV irradiated, and
whole-cell lysates from time points from 0 to 10 min postirradiation were probed for the indicated endogenous antigens.
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repair also fail to efficiently degrade Cdt1 (Fig. 5A and B). To
investigate the mechanism of Cdt1 stabilization by MAP ki-
nases, we prepared recombinant Cdt1-GST fusions expressing
wild-type Cdt1, the unphosphorylatable Cdt1-5A, and the
phosphomimetic Cdt1-2E3D. For a control, we included a
mutant form of Cdt1 that cannot bind PCNA, Cdt1PIPm (30).
We tested these proteins for binding to PCNA and Cdt2 in
chromatin fractions of UV-treated cells that were sonicated to
produce soluble chromatin fragments. As expected, UV in-
duced the chromatin loading of both PCNA and Cdt2 (Fig. 5C,
lanes 1 and 2) but had no effect on chromatin loading of MCM
subunit 2 (Mcm2) (18). Disruption of the PCNA binding site
eliminated PCNA binding to Cdt1, which correspondingly
eliminated recruitment of Cdt2 to the Cdt1-PCNA complex
(Fig. 5C, lane 8), demonstrating that this in vitro binding assay
recapitulates the interactions that occur in vivo. Both wild-type
Cdt1 and Cdt1-5A bound PCNA and Cdt2 equally well (Fig.
5C, lanes 6 and 12). Importantly, the phosphomimetic Cdt1-
2E3D showed normal binding to PCNA but severely impaired
recruitment of Cdt2 (Fig. 5C, lane 10). None of the mutations
affected Cdt1 binding to Mcm2 in this assay. Overall, we con-
clude that MAP kinase phosphorylation sites induce Cdt1 sta-
bilization by blocking the Cdt1-Cdt2 interaction and not the
Cdt1-PCNA interaction.
Since Cdt1 degradation during S phase can also be triggered
by CRL4Cdt2 (in conjunction with CRL1Skp2 [54]), the mech-
anism of Cdt1 protection from UV-induced degradation may
also apply to S-phase degradation. Likewise, since the stress
MAP kinases are active in G2 phase, phosphorylation of Cdt1
in G2 may have effects similar to the effects of phosphorylation
of Cdt1 in acutely stressed cells. We therefore tested whether
mutation of the MAP kinase phosphorylation sites affects Cdt1
stability during the transition between S phase and G2 phase.
To separate Cdt1 ubiquitination by CRL4Cdt2 from ubiquiti-
nation by CRL1Skp2, we combined the phosphorylation site
mutations with a mutation in the CDK binding site at positions
68 to 70 of Cdt1 (Cy motif). This mutation of the Cy motif
effectively blocks Cdt1 phosphorylation by CDKs, and thus,
Cdt1 does not bind the Cul1 adaptor Skp2 during S phase (45).
We generated stable cell lines expressing these new forms
FIG. 5. Phosphorylation blocks Cdt1 association with Cdt2 and controls Cdt1 stability during S phase. (A) In the case of UV-induced damage,
a collection of nucleotide excision repair factors that includes the Xeroderma pigmentosum group A (XPA) protein remove the damaged region,
creating a substrate for PCNA loading, Cdt1 interaction, and recruitment of the CRL4Cdt2 ubiquitin E3 ligase via the Cdt2 adaptor. TFIIH,
transcription factor IIH; RFC, replication factor complex. (B) UV-induced Cdt1 degradation was monitored by immunoblotting whole-cell lysates
of cells derived from patients with a profound XPA deficiency (XPA –def.) that are hence also PCNA loading deficient (3). Cdt1 degradation was
compared to degradation in derivatives of those cells reconstituted with the normal XPA cDNA (XPA ). (C) C-terminal GST fusions of wild-type
and mutant Cdt1 were partially purified from E. coli and incubated with sonicated chromatin fragments from untreated and UV-irradiated cells.
Cdt1PIPm is Cdt1 with a three-amino acid substitution in the PCNA-interacting motif (30). Association of endogenous PCNA, Cdt2, and Mcm2
with GST alone (lanes 3 and 4) or GST-Cdt1 fusion proteins was monitored by immunoblotting, and the isolated GST-Cdt1 proteins were detected
by Coomassie blue staining. (D) Stable derivatives of HeLa cells were created with a cyclin-dependent kinase (CDK)-resistant form of Cdt1 that
lacks the cyclin/CDK binding site at amino acids 68 to 70 (Cy motif). These Cdt1 constructs also bear mutations in MAP kinase phosphorylation
sites as indicated. These cell lines were then synchronized in early S phase by double thymidine block (time zero). Cells were released from the
early S block into transfection medium to deplete endogenous Cdt1, and samples were collected from 7 h until 9 h after release to monitor Cdt1
phosphorylation and accumulation during late S and G2. Whole-cell lysates were probed to detect Cdt1 by immunoblotting. The positions of
nonspecific bands that serve as loading controls are indicated by asterisks to the left of the gel.
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(Cy-Cdt1, Cy-Cdt1-5A, and Cy-Cdt1-2E3D) and eliminated
endogenous Cdt1 by siRNA transfection during release from
an early S-phase block as in Fig. 3C. By 7 h after release from
the thymidine arrest, S phase was nearly complete, and Cy-
Cdt1 began to reaccumulate (Fig. 5D, lane 3). Between 8 and
9 h postrelease, the amount of Cy-Cdt1 protein was substan-
tially increased relative to early S phase (Fig. 5D, compare
lanes 5 to 7 to lane 2). In contrast, the Cy-Cdt1-5A mutant
protein did not show the same phosphorylation shift in S phase
or G2, and the kinetics of Cdt1 reaccumulation were consis-
tently delayed relative to normal Cdt1 (Fig. 5D, compare lanes
10 to 14 to lanes 3 to 7). In marked contrast, the phosphomi-
metic Cy-Cdt1-2E3D protein was not efficiently downregulated
in S phase (Fig. 5D, lanes 23 to 28). These patterns of S-phase
degradation and reaccumulation indicate that MAP kinase-
dependent Cdt1 phosphorylation influences Cdt1 stability not
only in response to DNA damage but also during S phase
and G2.
p38 and JNK activities contribute to stress-induced inhibi-
tion of MCM loading. The finding that an essential origin
licensing protein is regulated by p38 and JNK MAP kinases
prompted us to investigate a potential role for these activities
in regulating origin licensing. To test this idea, we utilized
HCT-116 cells which can be readily synchronized in G1 by
serum deprivation and restimulation. We prepared both
whole-cell lysates (total) and chromatin-enriched fractions
from G1 cultures. Chromatin association for these experiments
is defined as resistance to extraction with nonionic detergent
but subsequent susceptibility to solubilization with nuclease
(see Materials and Methods for details.) In low-serum me-
dium, Mcm2 was abundant but not significantly associated with
chromatin (Fig. 6A, lane 1), and serum stimulation for 3.5 h
induced robust MCM chromatin association (Fig. 6A, lane 3).
We also probed whole-cell lysates of these cells with antibody
to phosphorylated MAPKAP-K2 and observed, as had been
reported previously (26), that at least one isoform of stress
MAP kinase, p38, is active in quiescent cells (Fig. 6A, lane 1).
Interestingly, phosphorylation of both MAPKAP-K2 and Cdt1
sharply declined just as Mcm2 became chromatin loaded (Fig.
6A, compare lanes 2 and 3). Addition of sorbitol 3 h after
serum addition but just prior to MCM loading acutely acti-
vated stress MAP kinases and efficiently blocked MCM loading
but had no effect on ORC subunit 2 (Orc2) chromatin associ-
ation (Fig. 6A, compare lanes 3 and 4). These results are
consistent with prior observations that osmotic stress by NaCl
addition to G1 cells prevents MCM loading (35). To determine
whether p38 and JNK have a role in this inhibition, we either
treated the cells with MAP kinase inhibitors 15 min prior to
sorbitol addition (Fig. 6A, lane 5) or transfected cells with
siRNAs to deplete p38 and p38 plus JNK1 and JNK2 during
the serum deprivation period (Fig. 6A, lane 6). Depletion of
both p38 and JNK or inhibiting their activities had no effect on
MCM loading in unstressed cells (data not shown), but strik-
ingly, inhibition of MAP kinase activity prior to sorbitol treat-
ment rescued MCM loading in G1 (Fig. 6A, compare lanes 5
and 6 with lane 4). We obtained very similar results using
FIG. 6. Stress MAP kinases inhibit MCM loading. (A) HCT-116 cells were synchronized in G0/G1 by serum deprivation and then restimulated
with serum for the indicated number of hours. Where indicated, sorbitol was added to a concentration of 0.35 M 3 h after stimulation with serum.
A mixture of p38 and JNK inhibitors was added 15 min before sorbitol addition to the cells in lane 5. The cells in lane 6 were transfected with
a mixture of four siRNAs targeting p38 and p38 plus JNK1 and JNK2 24 h prior to serum stimulation. Whole-cell lysates (total) and chromatin
fractions were analyzed for the indicated endogenous proteins by immunoblotting. (B) As in panel A except that LPS was added to 100 ng/ml 3 h
after serum stimulation instead of sorbitol.
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lipopolysaccharide (LPS) to activate MAP kinases instead of
sorbitol (Fig. 6B). Thus, activation of p38 and JNK during G1
can block MCM loading.
The phosphomimetic Cdt1 mutant has reduced function.
Since Cdt1 is a direct target of p38 and JNK, we sought to
determine whether stress-induced phosphorylation affects
Cdt1 function in loading MCM complexes. We suppressed
endogenous Cdt1 expression by siRNA transfection in asyn-
chronous cells stably expressing normal or mutant Cdt1. We
then evaluated DNA content and DNA synthesis by bromode-
oxyuridine (BrdU) incorporation 80 h after transfection. The
distribution of G1, S, and G2 populations in the five cell lines
is plotted in Fig. 7A; plots from a representative experiment
are shown in Fig. 7B. As expected, profound depletion of Cdt1
protein resulted in a severe reduction in the S-phase popula-
tion due to failed origin licensing in G1, and expression of
normal Cdt1 complemented this defect (Fig. 7A and B). The
unphosphorylatable Cdt1-5A mutant supported apparently
normal DNA synthesis, meaning that neither phosphorylation
of Cdt1 at these sites nor the presence of these specific serines
and threonines is strictly required for S-phase entry and pro-
gression (Fig. 7A, 5A bar, and Fig. 7B, 5A panel). On the other
hand, cells expressing only the phosphomimetic Cdt1-2E3D
had half as many S-phase cells as cells expressing normal Cdt1
and an increase in both G1 and G2 populations (Fig. 7A).
Moreover, cells expressing Cdt1-2E3D did not produce the
same high levels of BrdU incorporation as cells expressing
normal Cdt1. (BrdU intensity is plotted on a logarithmic
scale.) Thus, even when these mutant cells did enter S phase
(we presume that HCT-116 cells, like all other tumor-derived
cell lines tested [27, 46, 52, 60], fail the origin licensing check-
point), DNA synthesis was much less efficient.
We next measured the ability of the phosphomimetic Cdt1
mutant to support MCM chromatin loading. Whole-cell lysates
and chromatin fractions were prepared from the asynchronous
cultures shown in Fig. 7A and probed for endogenous Mcm2
and for Cdt1 (Fig. 7C). Cdt1 knockdown resulted in a severe
defect in MCM chromatin association, and wild-type Cdt1 and
Cdt1-5A fully complemented this phenotype (Fig. 7C, lanes 2
to 4). In marked contrast to both wild-type Cdt1 and Cdt1-5A,
the Cdt1-2E3D mutant was severely compromised for MCM
loading (Fig. 7C, lane 5). Reduced MCM loading is predicted
to result in fewer licensed origins, which could readily explain
the markedly lower rates of BrdU incorporation in Fig. 7B. If
the negative charge substitutions at the five phosphorylation
sites indeed mimic the effects of Cdt1 phosphorylation by MAP
kinases—as they clearly do for Cdt1 stability—then MAP ki-
nase-mediated phosphorylation inhibits Cdt1 function in
MCM loading.
FIG. 7. The phosphomimetic Cdt1 mutant is hypomorphic for MCM loading and DNA replication. (A) HCT-116 cells stably expressing WT
Cdt1, Cdt1-5A (unphosphorylatable), or Cdt1-2E3D (phosphomimetic mutant) were treated with siRNA targeting endogenous Cdt1 or GST as
a control for 80 h and labeled with bromodeoxyuridine (BrdU) for the final hour. DNA content and DNA synthesis were evaluated by flow
cytometry using anti-BrdU and propidium iodide. The average proportion of cells in each cell cycle phase was quantified from gated populations
of three independent experiments. The standard errors of the means for the cell populations in the G1, S, and G2 cell cycle phases, respectively,
are the following: 3.5, 5.1, and 3.0 for control siRNA; 6.5, 2.9, and 6.1 for empty vector plus siRNA targeting cdt1 (si-cdt1); 3.8, 0.6, and 3.9 for
WT Cdt1 plus si-cdt1; 0.8, 1.8, and 1.2 for Cdt1-5A plus si-cdt1; and 5.9, 8.4, and 3.0 for Cdt1-2E3D plus si-cdt1. Asterisks indicate statistical
significance (P 	 0.05) determined by paired Student’s t test. (B) Two-dimensional histograms of cell lines transfected with control siRNA or cdt1
siRNA expressing siRNA-resistant WT Cdt1, Cdt1-5A, Cdt1-2E3D, or empty vector. The y axis shows DNA synthesis as measured by fluorescein
isothiocyanate (FITC)-conjugated anti-BrdU signal on a logarithmic scale, and the linear x axis shows DNA content measured by propidium iodide
staining. (C) The cell lines in panel A were depleted of endogenous Cdt1 with siRNA for 80 h. Chromatin fractions and whole-cell lysates (total)
were analyzed for Mcm2 and Cdt1. (D) Model of MAPK-dependent phosphorylation of Cdt1. MAPK-dependent phosphorylation of Cdt1 has two
biological consequences: protection from CRL4Cdt2-mediated degradation and functional inhibition. P, phosphate; ORC, origin recognition
complex.
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DISCUSSION
We have demonstrated here that the Cdt1 DNA replication
licensing factor is a substrate for stress-activated mitogen-acti-
vated protein (MAP) kinases. The consequences of this phos-
phorylation are 2-fold: resistance to CRL4Cdt2-mediated degra-
dation and reduced activity for minichromosome maintenance
(MCM) loading.
Though p38 and JNK MAP kinases have been extensively
studied in response to acute cellular stresses, additional studies
have shown that these kinases are active in G2 during normal
cell cycles even in the absence of exogenous stress (12, 14, 29,
42, 65). Cdt1 is phosphorylated by MAP kinases during G2
phase, and our findings indicate that phosphorylation contrib-
utes to both inactivation of Cdt1 and Cdt1 reaccumulation
once DNA replication is complete. Since Cdt1 reaccumulates
in G2/M, but MCM complexes are not normally reloaded until
the next G1 phase, we suggest that MAP kinase kinase-medi-
ated Cdt1 phosphorylation serves to inactivate licensing in
cooperation with the inhibitory effects of Cdk-mediated phos-
phorylation of multiple origin licensing proteins and accumu-
lation of geminin.
Neither phosphorylated Cdt1 nor the Cdt1-2E3D phospho-
mimetic are degraded in UV-irradiated cells. Why would cel-
lular stress inactivate Cdt1 by phosphorylation rather than
trigger Cdt1 destruction as occurs after DNA damage? Cdt1
destruction requires either phosphorylation by cyclin A/Cdk2
or interaction with loaded PCNA (54), and neither is neces-
sarily available during a cellular stress response. Thus, inhibi-
tion by phosphorylation may have evolved as an alternative
mechanism to inactivate origin licensing. Inhibiting Cdt1 by
phosphorylation rather than through degradation could also
provide opportunities for rapid recovery from stress or rapid
reactivation of the G2/M-stabilized Cdt1 once cells complete
mitosis. Phosphorylated Cdt1 is also resistant to DNA damage-
induced degradation because the mechanism by which Cdt1 is
degraded after DNA damage is the same mechanism that
targets Cdt1 during S phase. We note that the stabilization of
PR-Set7 and p21, combined with the finding that p21 is also a
confirmed MAP kinase substrate (40), suggests a general
mechanism to control CRL4Cdt2 targets. Moreover, the pur-
pose of active stabilization of Cdt1 (and possibly other
CRL4Cdt2 targets) during G2 could be to facilitate efficient
licensing in the subsequent G1 phase or possibly to permit an
alternate late cell cycle function. For example, the PR-Set7/
Set8 methyltransferase is one CRL4Cdt2 target that we dem-
onstrate here is protected by MAP kinase activity, and PR-
Set7/Set8 has documented roles in both origin licensing and
chromatin compaction during G2 and M phases (11). Rapid
stabilization of PR-Set7/Set8 and other CRL4Cdt2 targets after
S phase completes may promote efficient execution of late cell
cycle events. The fact that null alleles of the Drosophila mela-
nogaster Cdt1 ortholog, “double-parked,” enter but cannot ex-
ecute mitosis (71) hints at a possible late cell cycle role for
Cdt1, but rigorous testing for such a role requires further
investigation. The Cdk inhibitor p21 clearly has roles in more
than one cell cycle phase also.
The fact that the Cdt1 phosphomimetic mutant very closely
recapitulates the effects of bona fide phosphorylation on Cdt1
stability strongly argues that these mutations also recapitulate
functional effects of Cdt1 phosphorylation and by inference
that phosphorylated Cdt1 has less activity than unphosphoryl-
ated Cdt1 does. Despite the hyperstability of the phosphomi-
metic protein, cells expressing Cdt1-2E3D do not show a sig-
nificantly higher propensity to rereplicate than cells expressing
normal Cdt1 either when expressed alone or in combination
with geminin depletion, and the same holds true for Cdt1-5A
(data not shown). We interpret these results in light of the
opposing effects of phosphorylation on Cdt1 function and sta-
bility and as further support for reduced function of the phos-
phomimetic mutant. The coincidence of Cdt1 phosphorylation
in G2 phase when MCM loading is inhibited provides addi-
tional circumstantial evidence for a model in which MAP ki-
nase-dependent phosphorylation facilitates the accumulation
of Cdt1 at the end of S phase but holds Cdt1 in a low-activity
form. In that regard, Cdt1 phosphorylation during G2 may
serve as an additional means to avoid relicensing and rerepli-
cation when S-phase destruction is no longer an option due to
the lack of loaded PCNA.
While this article was being prepared, Miotto and Struhl
reported Cdt1 phosphorylation at T29 by JNK1 in response to
acute cellular stress (50). Those authors found that phosphor-
ylation of Cdt1 interfered with its recruitment of the HBO1
acetylase to origins. Interestingly, the T29 phosphorylation site
which has previously been thought to be a CDK site (63) may
not be efficiently recognized by p38 (Fig. 3A), nor is it respon-
sible for the G2 or stress-induced gel mobility shift (Fig. 3B and
C). The T29 site is distinct from the five phosphorylation sites
that we investigated in this study, though one of the five (S391)
was also identified in the Miotto and Struhl study by mass
spectrometry (peptides containing the other 4 sites were not
measured). We confirmed phosphorylation of the majority of
the five C-terminal sites using site-specific phosphorylation-
sensitive antibodies; thus, it may be that Cdt1 is phosphory-
lated on as many as six amino acids by one or both stress MAP
kinases. JNK could be primarily responsible for T29 phosphor-
ylation to block HBO1 binding, while both p38 and JNK phos-
phorylate the five sites near the MCM binding domain to block
MCM loading by an additional mechanism.
Regarding the mechanism for Cdt1 inhibition, analysis of
chromatin-enriched cellular fractions from synchronized G1
cells revealed no stress-induced differences in Cdt1 chromatin
association nor substantial induction of the Cdt1 inhibitor
geminin (data not shown). We also found no effect of phos-
phorylation on the ability of Cdt1 to bind its partner licensing
proteins or geminin in endogenous coimmunoprecipitation ex-
periments (data not shown), and GST fusions to the phospho-
mimetic mutant bind Cdc6, ORC, and MCM subunits (Fig. 5C
and data not shown). Four of the five phosphorylation sites
(S391, T402, T406, and S411) lie in a flexible region of Cdt1
(36, 39) that is sufficient for Mcm6 binding in vitro (70). Cdt1
is a highly dynamic protein both in vivo (72) and in a recon-
stituted MCM loading assay using purified Saccharomyces
cerevisiae proteins (56) consistent with a model in which Cdt1
rapidly shuttles between the nucleoplasm and an origin-bound
ORC-Cdc6 loading machine. Cdt1 phosphorylation may dis-
rupt conformational changes required during these cycles of
MCM recruitment, loading, and release. The newly revealed
importance of these particular amino acids in Cdt1 function
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may also be useful in future mechanistic studies of the MCM
loading event.
It had previously been shown that activation of the stress
kinase pathway during G1 is sufficient to block S-phase entry,
but MCM loading was not examined in that study (24). More-
over, Iizuka et al. found that osmotic stress can block MCM
loading, but that study did not explore a role for stress-acti-
vated MAP kinases (35). On the basis of the low activity of the
phosphomimetic mutant, we suggest that Cdt1 phosphoryla-
tion by stress-activated kinases is one event that links MAP
kinase activity to inhibition of origin licensing. If so, then our
discovery (plus that of Miotto and Struhl [50]) mark the first
posttranslational modifications of Cdt1 shown to control mam-
malian Cdt1 function in MCM loading. Interestingly, the un-
phosphorylatable Cdt1-5A mutant does not render cells resis-
tant to acute stress (data not shown), and we hypothesize that
Cdt1 is not the only licensing protein regulated during a stress
response. For instance, each of the MCM subunits themselves
has conserved candidate MAP kinase phosphorylation sites
that could be additional targets (unpublished observations).
We have primarily utilized osmotic stress to activate p38 and
JNK in this study, but a great many extracellular signals and
cell cycle checkpoints are channeled through p38 and/or JNK.
The knowledge that once activated, these kinases regulate
Cdt1 and origin licensing will shed important light on the
cellular effects of such signaling pathways. The stress MAP
kinases are important not only for the response to acute cel-
lular insults and in G2 phase which we have investigated here
but they also play key roles in pathways controlling differenti-
ation, migration, proliferation, apoptosis, cell morphology, and
the immune response, and the coordination of these responses
is extraordinarily complex (19, 38, 41, 68). This new interface
of stress signaling activities with origin licensing suggests that
the replication licensing system is intimately integrated with
multiple pathways of information flow within the cell to pre-
serve genome integrity under a wide variety of situations. Con-
tinued investigation may reveal other specific examples of such
coordination that will contribute to a comprehensive under-
standing of dynamic replication licensing control in vivo.
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